[23]–[27] A recent metanalysis was in favour of lower serum urate levels in MS than in healthy subjects and neurological controls [28] Furthermore, in a recent clinical trial, the combination of interferon beta and inosine was safe and well tolerated but did not provide any additional benefit on accumulation of disability compared with interferon beta alone. [29] Based on these observations, the effective contribute of urate to the pathogenesis of MS still remains unclear. This evidence concerns the gene IFNB1 and myeloid sarcoma.